32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Currently constant discounting rate of 3.5 percent is applied for discounting the costs and outcomes in the UK. This study applied different approaches such as empirical, stepwise and time-shifted discounting in parallel to the constant discounting and identify their impact on cost-effectiveness with respect to the NICE threshold. The decision tree and Markov model were built for the UK population cohort followed for the lifetime. Only chronic patients were included in the model. The different discounting approaches were applied to the costs and health outcomes. The Incremental Cost…mehr

Produktbeschreibung
Currently constant discounting rate of 3.5 percent is applied for discounting the costs and outcomes in the UK. This study applied different approaches such as empirical, stepwise and time-shifted discounting in parallel to the constant discounting and identify their impact on cost-effectiveness with respect to the NICE threshold. The decision tree and Markov model were built for the UK population cohort followed for the lifetime. Only chronic patients were included in the model. The different discounting approaches were applied to the costs and health outcomes. The Incremental Cost Effectiveness Ratios (ICERs) thus obtained were compared. This study was thus able to identify the approach which led to favourable ICERs.This study can specifically answer why different approaches are required for vaccines compared to drugs.
Autorenporträt
Durgesh N. Kahol studied Economic Evaluation in Healthcare at City University, London. She worked with IMS Health as an analyst in the HEOR team. Prior to this she worked as an analyst at Kinapse- a lifesciences consulting firm working on projects for top 5 global pharma. She also holds a MBA degree(Pharma Management) and Bachelor of Pharmacy.